13F Holdings
中文EN

UPC Universe Pharmaceuticals INC Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1809616 · Fiscal year ends 09/30

Financial factors as of 2025-09-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-22.4%
TTM net income YoY57.9%
TTM EPS YoY98.7%
Revenue 3-yr CAGR663.4%
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-16.3%
Net margin-20.6%
FCF margin-29.8%
EBITDA margin-13.4%

Returns

ROE-7.2%
ROA-5.4%
ROIC (approx.)-12.0%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets19.0%
Debt / equity0.00x
Current ratio4.07x
Interest coverage-10.08x

Cash quality & payout

Operating cash flow / net income1.38x
Accruals ratio2.0%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue$17.86B$23.02B$32.31B$40.14M$47.98M
Cost of revenue$11.56B$16.95B$21.99B$18.25M$22.66M
Gross profit$6.30B$6.07B$10.32B$21.89M$25.33M
R&D expense$671.76M$3.03B$4.86B$7.64M$5.47M
SG&A expense$3.75B$2.89B$2.64B$2.18M$3.30M
Operating income-$2.92B-$8.02B-$3.97B-$7.02M$13.59M
Interest expense$289.38M$304.52M$190.18M$162,400$101,604
Pretax income-$3.67B-$8.12B-$4.33B-$7.09M$13.68M
Income tax—$606.70M$2.25B$815,322$2.36M
Net income-$3.67B-$8.73B-$6.58B-$7.91M$11.32M
EBITDA-$2.40B-$7.53B-$3.46B-$6.49M$14.04M
EPS (basic)-8.06-626.96-1,089.21-1,309.113.58
EPS (diluted)-8.06-626.96-1,089.21-1,309.113.58
Weighted avg. shares (diluted)455,87113,9206,0426,0423.16M
Balance sheet
Cash & equivalents$33.59B$29.50B$5.29B$5.71B$8.08M
Short-term investments——$13.22M$13.15M$13.73M
Receivables$13.01B$12.91B$11.01M$15.18M$15.57M
Inventory$2.19B$1.74B$3.34M$2.21M$2.46M
Current assets$53.60B$51.64B$25.27M$41.51M$50.48M
PP&E, net$3.58B$3.57B$3.70M$4.25M$4.68M
Intangibles$296.79M$262.88M$148,584$157,451$148,584
Total assets$69.30B$67.95B$41.72M$59.54M$70.14M
Current liabilities$13.17B$20.31B$13.75M$13.10M$11.21M
Short-term debt$2.11B$5.86B$5.48M$3.94M$4.33M
Total liabilities$13.17B$22.45B$13.75M-$35.27B$23.15M
Shareholders' equity$56.13B$45.50B$27.97B$35.33B$46.99M
Shares outstanding563,33842,8806,0623.62M21.75M
Cash flow statement
Operating cash flow-$5.05B-$9.51B$1.12B-$1.30M-$2.06M
Capital expenditure$266.77M$208.32M$44.17M$93,703$444,505
Free cash flow-$5.32B-$9.72B$1.07B-$1.40M-$2.50M
Investing cash flow-$341.81M-$361.29M-$44.17M-$3.91M-$27.06M
Financing cash flow$9.73B$33.95B-$1.39B$3.32M$26.58M
Depreciation & amortization$517.43M$485.73M$508.79M$533,949$446,878

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.